Cynvenio Signs Mexican Distribution Deal

Westlake Village clinical diagnostics developer Cynvenio Biosystems Inc. has signed an exclusive distribution deal with Mexico-based Milenia Labs, the companies announced Thursday. The deal will make Cynvenio’s ClearID Breast Cancer blood test available in Mexico solely through Milenia Labs, which has 12 diagnostic centers throughout the country. ClearID utilizes a sequencing panel of 27 genes known to be altered in breast cancer to identify genetic mutations for treatment. It is based on Cynvenio’s LiquidBiopsy platform, which analyzes DNA in the bloodstream to diagnose tumor progression. In addition to ClearID, Milenia will also offer Cynvenio’s PD-L1 gene expression reflex assay along with other products in the future. “We are excited to extend the reach of our tests and to help more patients receive advanced genomic testing and molecular monitoring in Mexico,” Humberto Huerta, Cynvenio’s chief commercial officer of clinical diagnostics, said in a statement. “This agreement is the cornerstone of our plan to broaden access to ClearID Breast testing services outside the United States.”